DU-176b
Phase 3Small molecule
Daiichi SankyoDU-176b is one of 102 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.
4
Indications
9
Total Trials
0
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1DU-176b
Daiichi SankyoPhase 3
Calquence
AstraZenecaPreclinical
Calan
VVal Adams
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Anticoagulants
SanofiPreclinical
Statin
Bristol-Myers SquibbPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Warfarin Sodium
Boehringer IngelheimPreclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Bupivacain
IIstanbul University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atrial Fibrillation3 trials
Total Knee Arthroplasty1 trial
Total Hip Replacement1 trial
2 more indications
Orthopedic Surgery1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DU-176b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company